by Ariana | Jun 24, 2024 | Article
Dr. Boilard and his team have determined that an SLE-prone environment alters bioenergetic functions and gene expression in bone marrow megakaryocytes (MK). The data obtained from the Lupus Canada Catalyst grant project had significant impact on Dr. Boilard’s team to...
by admin | May 4, 2024 | Article
May 1, 2024 – Lupus Canada is pleased to share that Lupus Awareness Month is kicking off with a Saphnelo listing in Saskatchewan effective May 1st, 2024. With this listing, Saphnelo is now covered by 86% of Canadian public drug reimbursement plans. For more...
by admin | May 4, 2024 | Article
April 30, 2024 – Lupus Canada is pleased to share updates to the Benlysta listing in the following provinces: NL – Criteria-Apr-2024.pdf (gov.nl.ca) AB – Full April 1, 2024 – Alberta Drug Benefit List (bluecross.ca) NIHB...
by admin | May 4, 2024 | Article
April 29, 2024 – Lupus Canada is pleased to share that Benlysta (indication Lupus Nephritis) is listed in Ontario effective April 17, 2024. SUMMARY OF PRODUCT CHANGES We are pleased to provide you with the Summary of Changes – April 2024 to Edition No. 43 of...
by admin | May 4, 2024 | Article
April 23, 2024 – Lupus Canada is pleased to share that Saphnelo has been listed in PEI effective April 23, 2024. For more information, please visit the PEI Pharmacare Program website.
